2-O-methyltransferase, Non-structure protein 16, covid-19, nsp16, sars-cov-2
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019-20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Methyltransferase mediates mRNA cap 2-O-ribose methylation to the 5-cap structure of viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16. Therefore plays an essential role in viral mRNAs cap methylation which is essential to evade immune system.
SARS-CoV-2 (COVID-19) NSP16 antibody is supplied in PBS containing 0.02% sodium azide.
Reinheit:
SARS-CoV-2 (COVID-19) NSP16 Antibody is affinity chromatography purified via peptide column.
Antibody Type:
Polyclonal Antibody
Anwendungsbeschreibung:
IHC: 0.5 µg/mL, WB: 0.5 µg/mLAntibody validated: Immunohistochemistry in human samples. SARS-CoV-2 (COVID-19) NSP16 antibody can detect 2 ng of free peptide at 1 µg/mL in ELISA. It can detect SARS-CoV-2 NSP16 recombinant protein by ELISA and WB. All other applications and species not yet tested.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
